<DOC>
	<DOCNO>NCT00093834</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's tumor cell may make body build immune response kill tumor cell . Drugs use chemotherapy , cyclophosphamide doxorubicin , work different way stop tumor cell divide stop grow die . Combining vaccine therapy cyclophosphamide doxorubicin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose cyclophosphamide doxorubicin give vaccine therapy treat woman stage IV breast cancer .</brief_summary>
	<brief_title>Vaccine Therapy With Without Cyclophosphamide Doxorubicin Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety vaccination comprise allogeneic sargramostim ( GM-CSF ) -secreting breast cancer cell without immunomodulation use cyclophosphamide doxorubicin woman stage IV breast cancer . - Determine dos cyclophosphamide doxorubicin maximize vaccine-induced immunity , term immune response HER2/neu , patient treat regimen . - Compare vivo immune response induce regimen , measure immunohistochemical analysis vaccine site biopsy patient , response see prior preclinical clinical study . Secondary - Determine time disease progression patient treat regimen . OUTLINE : This dose-finding study . The first 6 patient receive 1 2 dos vaccine comprise allogeneic sargramostim ( GM-CSF ) -secreting breast cancer cell intradermally ( ID ) day 0 . Subsequent patient receive cyclophosphamide IV day -1 , vaccine high dose ID day 0 , doxorubicin IV day 7 . Treatment patient repeat every 4-6 week 3 course absence disease progression unacceptable toxicity . Patients stable respond disease third course receive fourth course treatment approximately 4 month completion third course . Cohorts 2-3 patient receive fix dose vaccine combination escalate dos doxorubicin cyclophosphamide . Doses cyclophosphamide doxorubicin escalate optimal dose combination chemotherapy fix dose vaccine achieve . Patients follow 1 month 4 month completion study therapy annually thereafter . PROJECTED ACCRUAL : A total 6-60 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Stage IV disease Stable disease ≥ 28 day Measurable evaluable disease OR evidence disease Not eligible potentially curative therapy Adequately treat CNS metastasis allow Hormone receptor status : Not specify HER2/neu status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL ( unless due Gilbert 's syndrome ) AST ALT ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN Renal Creatinine &lt; 2.0 mg/dL Cardiovascular Ejection fraction ≥ 45 % echocardiogram MUGA Pulmonary Asthma chronic obstructive pulmonary disease allow provided daily systemic corticosteroid therapy require Immunologic No active autoimmune disease require systemic immunosuppressive therapy , include follow : Inflammatory bowel disease Systemic vasculitis Scleroderma Psoriasis Multiple sclerosis Hemolytic anemia Immunemediated thrombocytopenia Rheumatoid arthritis Systemic lupus erythematosus Sjögren 's syndrome Sarcoidosis Other rheumatologic disease HIV negative No active acute chronic infection No allergy corn Other No malignancy within past 5 year except carcinoma situ cervix , superficial nonmelanoma skin cancer , superficial bladder cancer No active major medical psychosocial problem would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy More 28 day since prior biologic therapy No concurrent biologic therapy , include trastuzumab ( Herceptin® ) Chemotherapy Prior adjuvant chemotherapy allow Prior doxorubicin cyclophosphamide allow Prior doxorubicin dose combine plan study therapy dose must exceed lifetime cumulative dose ≥ 450 mg/m^2 More 28 day since prior systemic chemotherapy No concurrent systemic chemotherapy Endocrine therapy More 28 day since prior systemic corticosteroid Concurrent hormonal endocrine therapy allow No concurrent systemic corticosteroid Radiotherapy More 28 day since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other More 28 day since prior participation another investigational drug trial No concurrent investigational drug Concurrent bisphosphonates allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>